TY - JOUR
T1 - Human Papillomavirus Vaccination Uptake in the Rio Grande Valley
T2 - Results from a Pilot Community-Based Educational and School-Based Vaccination Program and Its Expansion
AU - Rodriguez, Ana M.
AU - Do, Thuy Quynh N.
AU - Eyada, Mostafa F.
AU - Chen, Lu
AU - Schmeler, Kathleen M.
AU - Montealegre, Jane R.
N1 - Funding Information:
This cross-sectional study summarizes multiple projects funded by the Cancer Prevention Research Institute of Texas (CPRIT) to increase HPV vaccine uptake in the RGV (Texas). The goals were to meet the 2016 NIS-Teen HPV vaccination rates (initiation: 49.3%; completion: 32.9%) [,,]. The study period was from August 2016 to August 2022. The pilot project took place in Rio Grande City Consolidated Independent School District [RGCCISD] (3 middle schools) from 2016–2019 [,], and expanded into Pharr-San Juan-Alamo Independent School District [PSJA ISD] (8 middle schools) in 2019–2022 [], and Roma ISD (2 middle schools), Zapata ISD (1 middle school), San Isidro ISD (1 middle school), and Jim Hogg ISD (1 middle school) in 2020–2022. Approval for this program was obtained from the University of Texas Medical Branch’s Institutional Review Board (IRB-19–0138 on August 21, 2019; IRB-21–0044 approved on March 24, 2021) and the school boards for RGCCISD, PSJA ISD, Roma ISD, Zapata ISD, San Isidro ISD, and Jim Hogg ISD. Parental consent was obtained prior to vaccination and documented in our system.
Funding Information:
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH), the Cancer Prevention Institute of Texas (CPRIT) or The University of Texas MD Anderson Cancer Center’s HPV Vaccination Initiative. This research was funded by the Institute for Translational Sciences at the University of Texas Medical Branch, supported in part by a Clinical and Translational Science Award from the National Center for Advancing Translational Sciences, National Institutes of Health [grant number UL1 TR001439] and The University of Texas MD Anderson Cancer Center’s HPV Vaccination Initiative. In addition, AMR and KFK also received grant funding from The Cancer Prevention Research Institute of Texas [grant numbers PP160097, 2016; PP190023, 2019; PP200057, 2020]. Neither NIH, The University of Texas MD Anderson Cancer Center’s HPV Vaccination Initiative nor CPRIT have roles in the development of this article (i.e., in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication).
Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - Human papillomavirus (HPV) vaccine is a safe and effective strategy for reducing HPV morbidity and mortality. Schools have become an increasingly attractive setting for delivering vaccinations and supporting vaccination health literacy and decisional support. This study assesses the effectiveness of a community-based, physician-led HPV education campaign (starting in 2016) and onsite middle school-based HPV vaccination program across six school districts (2017, 2019, 2020) in a rural, medically underserved Texas area (Rio Grande Valley). Pre- and post-intervention HPV vaccination rates were tracked against the 2016 National Immunization Survey—Teen target rates (initiation: 49.3%; completion: 32.9%). Summary statistics were stratified by gender, school district, and grade level. The study reached 19,951 students who received HPV vaccines directly or indirectly through our program (10,289 females; 9662 males) (August 2016–August 2022). Of those, 2145 students (1074 females; 1071 males) were vaccinated directly through our program. The overall HPV up-to-date (UTD) rates were 58.8%. The overall median age at HPV vaccine initiation and HPV-UTD (range) was 11 years (9–21) and 12 years (9–20). The overall median interval between HPV vaccine doses (range) was 291 days (146–2968). Recommending HPV vaccine initiation at younger ages increases HPV vaccine completion and providing access to HPV vaccines encourages on-time vaccination and completion.
AB - Human papillomavirus (HPV) vaccine is a safe and effective strategy for reducing HPV morbidity and mortality. Schools have become an increasingly attractive setting for delivering vaccinations and supporting vaccination health literacy and decisional support. This study assesses the effectiveness of a community-based, physician-led HPV education campaign (starting in 2016) and onsite middle school-based HPV vaccination program across six school districts (2017, 2019, 2020) in a rural, medically underserved Texas area (Rio Grande Valley). Pre- and post-intervention HPV vaccination rates were tracked against the 2016 National Immunization Survey—Teen target rates (initiation: 49.3%; completion: 32.9%). Summary statistics were stratified by gender, school district, and grade level. The study reached 19,951 students who received HPV vaccines directly or indirectly through our program (10,289 females; 9662 males) (August 2016–August 2022). Of those, 2145 students (1074 females; 1071 males) were vaccinated directly through our program. The overall HPV up-to-date (UTD) rates were 58.8%. The overall median age at HPV vaccine initiation and HPV-UTD (range) was 11 years (9–21) and 12 years (9–20). The overall median interval between HPV vaccine doses (range) was 291 days (146–2968). Recommending HPV vaccine initiation at younger ages increases HPV vaccine completion and providing access to HPV vaccines encourages on-time vaccination and completion.
KW - adolescent health
KW - human papillomavirus vaccine
KW - human papillomavirus-related cancers and diseases
KW - provider recommendation
KW - Rio Grande Valley
KW - school-based vaccination
UR - http://www.scopus.com/inward/record.url?scp=85149234526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149234526&partnerID=8YFLogxK
U2 - 10.3390/vaccines11020329
DO - 10.3390/vaccines11020329
M3 - Article
AN - SCOPUS:85149234526
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 2
M1 - 329
ER -